BRPI0411245A - composto, composição farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de vìrus oncogênicos e para tratamento ou profilaxia de condições ou distúrbios devidos a infecção por hpv - Google Patents

composto, composição farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de vìrus oncogênicos e para tratamento ou profilaxia de condições ou distúrbios devidos a infecção por hpv

Info

Publication number
BRPI0411245A
BRPI0411245A BRPI0411245-8A BRPI0411245A BRPI0411245A BR PI0411245 A BRPI0411245 A BR PI0411245A BR PI0411245 A BRPI0411245 A BR PI0411245A BR PI0411245 A BRPI0411245 A BR PI0411245A
Authority
BR
Brazil
Prior art keywords
treatment
compound
prophylaxis
methods
pharmaceutical composition
Prior art date
Application number
BRPI0411245-8A
Other languages
English (en)
Inventor
Sharon Davis Boggs
Kristjan S Gudmundsson
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of BRPI0411245A publication Critical patent/BRPI0411245A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, USO DE UM COMPOSTO, E, MéTODOS PARA TRATAMENTO OU PROFILAXIA DE VìRUS ONCOGêNICOS E PARA TRATAMENTO OU PROFILAXIA DE CONDIçõES OU DISTúRBIOS DEVIDOS A INFECçãO POR HPV". A presente invenção refere-se a novos compostos de Fórmula que são úteis no tratamento dos papilomavírus humanos, e também a métodos para a produção e uso de tais compostos.
BRPI0411245-8A 2003-06-12 2004-06-07 composto, composição farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de vìrus oncogênicos e para tratamento ou profilaxia de condições ou distúrbios devidos a infecção por hpv BRPI0411245A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47797203P 2003-06-12 2003-06-12
US49778703P 2003-08-26 2003-08-26
PCT/US2004/018180 WO2005005386A1 (en) 2003-06-12 2004-06-07 Tetrahydrocarbazole derivatives and their pharmaceutical use

Publications (1)

Publication Number Publication Date
BRPI0411245A true BRPI0411245A (pt) 2006-07-18

Family

ID=34068099

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411245-8A BRPI0411245A (pt) 2003-06-12 2004-06-07 composto, composição farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de vìrus oncogênicos e para tratamento ou profilaxia de condições ou distúrbios devidos a infecção por hpv

Country Status (15)

Country Link
US (1) US7419997B2 (pt)
EP (1) EP1646610B1 (pt)
JP (1) JP2007500750A (pt)
KR (1) KR20060017544A (pt)
AU (1) AU2004256052A1 (pt)
BR (1) BRPI0411245A (pt)
CA (1) CA2528336A1 (pt)
CO (1) CO5660264A2 (pt)
DE (1) DE602004022169D1 (pt)
ES (1) ES2327416T3 (pt)
IL (1) IL172087A0 (pt)
MA (1) MA27879A1 (pt)
NO (1) NO20055750L (pt)
RU (1) RU2005138126A (pt)
WO (1) WO2005005386A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1678137A1 (en) * 2003-10-15 2006-07-12 Chiron Corporation Compositions and methods for viral inhibition
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
AU2005222632B2 (en) 2004-03-15 2012-02-09 Ptc Therapeutics, Inc. Carboline derivatives useful in the inhibition of angiogenesis
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
WO2006012310A2 (en) * 2004-06-25 2006-02-02 Genzyme Corporation Carbazole derivatives for treating polycystic kidney disease
US20090170906A1 (en) * 2004-11-22 2009-07-02 Kristjan Gudmundsson Hcv inhibitors
CA2588389A1 (en) * 2004-11-23 2006-06-22 Ptc Therapeutics, Inc. Substituted phenols as active agents inhibiting vegf production
WO2019005841A1 (en) * 2017-06-26 2019-01-03 Rutgers, The State University Of New Jersey THERAPEUTIC COMPOUNDS AND METHODS FOR TREATING INFECTION
US10882821B1 (en) 2017-09-26 2021-01-05 The Board Of Trustees Of The Leland Stanford Junior University Enantiomeric compound for the reduction of the deleterious activity of extended nucleotide repeat containing genes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9008108D0 (en) * 1990-04-10 1990-06-06 Bayer Ag Cycloalkano(b)dihydroindoles and-indolesulphonamides substituted by heterocycles
US5100891A (en) * 1991-01-18 1992-03-31 Hoechst-Roussel Pharmaceuticals Inc. Substituted 1,2,3,4-tetrahydrocyclopent[b]indoles, 1,2,3,3a,4,8a-hexahydrocyclopent[B]indoles and related compounds
GB0015904D0 (en) * 2000-06-28 2000-08-23 Hoffmann La Roche Inhibitors of HPV E1 helicase enzyme
DE10164564B4 (de) 2001-12-14 2007-05-16 Zentaris Gmbh Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR)

Also Published As

Publication number Publication date
RU2005138126A (ru) 2006-07-27
ES2327416T3 (es) 2009-10-29
MA27879A1 (fr) 2006-05-02
KR20060017544A (ko) 2006-02-23
EP1646610B1 (en) 2009-07-22
US20060148857A1 (en) 2006-07-06
NO20055750D0 (no) 2005-12-05
US7419997B2 (en) 2008-09-02
IL172087A0 (en) 2009-02-11
NO20055750L (no) 2006-01-06
EP1646610A1 (en) 2006-04-19
AU2004256052A1 (en) 2005-01-20
WO2005005386A1 (en) 2005-01-20
CO5660264A2 (es) 2006-07-31
JP2007500750A (ja) 2007-01-18
DE602004022169D1 (de) 2009-09-03
CA2528336A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
DE60219954D1 (de) Neue Indol-2-on Derivate
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
DE60229530D1 (de) Substituierte piperazine als modulatoren des melanocortinrezeptors
AP2003002915A0 (en) HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis.
NO20063275L (no) Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom
BRPI0409969A (pt) composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
BRPI0408369A (pt) derivados de indol úteis para o tratamento de doenças
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
BR0211122A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BR0316771A (pt) Compostos para o tratamento ou a prevenção de infecções por flavivirus, uso de um composto e composição farmacêutica
DE60003863D1 (de) Dioxocyclopentylhydroxamsäure
BRPI0412893A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de prevenção, tratamento ou melhora de doenças ou condições inflamatórias, ou doenças ou condições oftálmicas, de tratamento ou melhora de cáncer e para a produção de um composto
SE0403006D0 (sv) New compounds
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BRPI0411085A (pt) composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de vìrus oncogênicos, e de condições ou distúrbios devidos a infecção por hpv
TW200716547A (en) Piperidin-4-yl-amide derivatives
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
BRPI0607214A2 (pt) derivados de 2-(4-cianofenilamino) pirimidina inibidores de hiv
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.